On Health Policy Archives

Comments to FDA on Proposed Delay of Compliance Date for Nutrition Rule and Serving Size Rule

November 1, 2017. The FDA has proposed to delay the compliance date for the Nutrition Rule and Serving Size Rules of May 2016. Our center believes that the proposed delay will be harmful to Americans. With growing diet-related chronic diseases, we need accurate labels and serving size information to make informed decisions. Read more here to find out why this is a bad proposal.

NCHR Comments on HHS Draft Strategic Plan FY2018-2022

October 26, 2017. The HHS has drafted a strategic plan for implementation over the next several years. We object to language that is non-scientific and themes which weight political rhetoric and ideology over sound scientific principles. Read more of our comments here.

NCHR Letter to the DC City Council on Artificial Turf

October 26, 2017. It is clear that city officials have assumed artificial turf products are safe because the salespeople told them they were safe. Unfortunately, there is clear scientific evidence that these materials are potentially harmful, and the only question is how harmful are they and how much exposure is likely to be harmful? Our children deserve better.

NCHR Comments at CDRH’s Voluntary Medical Device Manufacturing and Product Quality Workshop

October 10, 2017. Recalls demonstrate the crucial need for improved medical device quality, and for more clinical testing of such devices before they are put onto the marketplace, as well as improved inspections of manufacturing facilities prior to them going on the market. It’s a positive sign that this pilot program will address at least some of these inspectional issues.

NCHR Statement on Right To Try Legislation before the House Energy and Commerce Subcommittee on Health

October 3, 2017. We strongly urge this Committee to reject the Right To Try legislation that is currently under consideration, because it would undermine the successful FDA compassionate waiver program already in place to enable patients to have access to experimental drugs for free or at cost.